A groundbreaking approach presented at Europe's largest rheumatology conference could transform treatment for patients with severe, treatment-resistant autoimmune diseases by completely erasing the immune cells that drive these conditions. Instead of simply suppressing symptoms, scientists are now targeting the root cause: pathogenic B cells and plasma cells that hide in bone marrow and lymph nodes, where conventional therapies cannot reach them.

Why Standard Autoimmune Treatments Fall Short?

For more than 20 years, doctors have relied on a drug called rituximab to treat autoimmune diseases like rheumatoid arthritis, lupus, and Sjögren's syndrome. Rituximab works by targeting B cells, which are immune cells that produce the harmful antibodies driving autoimmune conditions. However, this approach has significant limitations that leave many patients with inadequate disease control.

The main problem is incomplete depletion. Rituximab depends on the body's own immune system to destroy the targeted B cells, but this mechanism frequently fails to reach cells hiding deep within tissue niches like bone marrow and lymph nodes. Additionally, rituximab cannot eliminate long-lived plasma cells, which are mature B cells that act as "autonomous autoantibody factories," continuously producing disease-causing antibodies entirely unaffected by conventional therapy.

"Rituximab has a very established treatment, but it has several shortcomings," said Wolfgang Merkt, MD, Division of Rheumatology at Heidelberg University. "These limitations include incomplete depletion within deep tissue such as the bone marrow and lymph nodes, target antigen internalization, antidrug antibody formation, and an inherent failure to reach CD20-negative, long-lived plasma cells."

Wolfgang Merkt, MD, Division of Rheumatology, Heidelberg University

What Are BiTEs and How Do They Work Differently?

To overcome these limitations, researchers are turning to a new class of engineered molecules called bispecific T-cell engagers, or BiTEs. Unlike traditional antibodies that simply bind to a target and hope the immune system notices, a BiTE is designed to actively force two different immune cells together.

A BiTE features two distinct arms. One arm locks onto a specific marker on B cells or plasma cells, while the other arm grabs onto T cells, which are another type of immune cell. By physically bringing these two cells close together, the BiTE bypasses the normal rules of immune activation. It tricks the T cell into recognizing the target cell as a hostile threat, triggering the formation of what scientists call a "synthetic cytotoxic synapse." The T cell then unleashes a wave of toxic proteins called perforins and granzymes that systematically dissolve the pathogenic B cell or plasma cell directly within its tissue niche.

How Are Researchers Testing These New Therapies?

At the European Alliance of Associations for Rheumatology (EULAR) 2026 Annual Meeting, researchers presented clinical data from patients with severe, multidrug-resistant autoimmune diseases who had exhausted all standard treatment options. One promising BiTE candidate is teclistamab, which targets a marker called BCMA found on mature plasma cells and plasmablasts.

A team at Universitätsklinikum Erlangen studied 18 patients with severe, progressive autoimmune diseases using teclistamab. The cohort included patients with systemic sclerosis, IgG4-related disease (a rare autoimmune condition), inflammatory myositis, rheumatoid arthritis, Sjögren's disease, and Graves' disease. Tissue biopsies confirmed complete elimination of plasma cells directly within bone marrow and lymph nodes, demonstrating that these new therapies can reach disease-causing cells in locations where conventional drugs cannot.

In one striking case, a young patient with severe Graves' disease (an autoimmune thyroid condition) who had already failed orbital decompression surgery, high-dose steroids, and mycophenolate mofetil experienced complete reversal of thyroid-stimulating hormone receptor autoantibodies to zero. The therapy fully normalized the patient's thyroid function and entirely averted a scheduled thyroidectomy.

What Are the Key Differences Between BiTE Approaches?

Researchers are exploring three distinct BiTE strategies, each with different strengths and tradeoffs:

• Teclistamab: This full-length antibody targets BCMA on plasma cells and has a longer circulatory half-life, allowing for periodic subcutaneous injections rather than continuous infusion. It achieved complete plasma cell depletion in deep tissue niches but caused hypogammaglobulinemia (low antibody levels) in 100% of treated patients, requiring intravenous immunoglobulin replacement.
• Blinatumomab: This small fragment-based molecule targets CD19 on B cells but has an exceptionally short half-life of approximately 2 hours, requiring continuous 24-hour intravenous infusion via a portable pump. While highly effective at clearing peripheral B cells, rapid repopulation from bone marrow precursors frequently leads to early clinical relapses.
• Mosunetuzumab: This full-length antibody targets CD20 on mature B cells while sparing the plasma cell niche, significantly reducing the risk for profound hypogammaglobulinemia compared to plasma cell-directed therapies.

What Safety Concerns Have Emerged?

While these therapies show remarkable efficacy, safety monitoring is essential. In the 18-patient cohort treated with teclistamab, cytokine release syndrome (CRS), a temporary inflammatory reaction, occurred in 83% of patients. However, all cases were low grade (grade 1 or 2) and successfully managed with tocilizumab, an interleukin-6 receptor antagonist. No cases of immune effector cell-associated neurotoxicity syndrome were observed.

The most significant safety consideration is hypogammaglobulinemia, which developed in all treated patients receiving teclistamab. This condition means patients have dangerously low levels of protective antibodies and require proactive management with intravenous immunoglobulin replacement to prevent serious infections.

Can These Therapies Achieve a True "Immune Reset"?

The ultimate goal of these new approaches is to achieve what researchers call an "immune reset," meaning complete eradication of pathogenic B cells and plasma cells within deep tissue niches, allowing a healthy, non-autoreactive immune system to grow back. However, experts caution that this goal may be more challenging than initially hoped.

"BiTEs are certainly more scalable and accessible compared to ex vivo manufactured chimeric antigen receptor T cells. But at the current stage, it is unclear whether BiTEs can induce a full immune reset. It seems that most patients eventually relapse, suggesting that full immune reset may be more challenging to achieve. However, not every BiTE is the same," said Hans Ulrich Scherer, MD, PhD, Professor of Translational Rheumatology at Leiden University Medical Center.

Hans Ulrich Scherer, MD, PhD, Professor of Translational Rheumatology, Leiden University Medical Center

What Does This Mean for Patients With Severe Autoimmune Disease?

For patients with treatment-resistant autoimmune diseases, these new BiTE therapies represent a fundamentally different approach. Rather than simply suppressing the immune system or blocking inflammatory signals, BiTEs actively eliminate the disease-causing cells themselves, potentially offering longer-lasting remission or even cure. The ability to reach cells hiding in bone marrow and lymph nodes addresses a critical gap in current treatment options.

While BiTEs are not yet widely available outside of clinical trials, the clinical data presented at EULAR 2026 demonstrates that this approach is feasible and can produce dramatic clinical improvements in patients who have exhausted conventional options. As research continues, these therapies may eventually become standard treatment for severe, refractory autoimmune diseases including rheumatoid arthritis, lupus, systemic sclerosis, and other conditions that currently have limited treatment options.